Sign In
Buy AZN
$176.43
+1.50 (+0.86%)
At Close: Jun 22, 2026
NYSE Content Update: AstraZeneca Celebrates Largest Transfer in NYSE History
08:55am, Friday, 05'th Jun 2026
NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, June 5, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NY
FTSE 100 drops amid China banking concerns and falling oil prices
08:57am, Thursday, 04'th Jun 2026
The UK's benchmark FTSE 100 index fell to its lowest level in more than two weeks on Thursday, weighed down by sharp declines in Asia-focused lenders and miners after reports of tighter offshore banki
Can AstraZeneca's Expanding Cancer Portfolio Sustain Momentum?
11:11am, Wednesday, 03'rd Jun 2026
AstraZeneca's oncology sales hit $6.8B in first-quarter 2026, fueled by key cancer drugs. New launches and late-stage pipeline assets support growth.
Leading Bank maintains sell on AstraZeneca at 11,500p as ASCO glow fails to resolve key pipeline questions
07:32am, Wednesday, 03'rd Jun 2026
Deutsche Bank has kept its sell rating and 11,500p price target on AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), the FTSE 100 pharmaceuticals giant, with the...
Leading Bank maintains sell on AstraZeneca at 11,500p as ASCO glow fails to resolve key pipeline questions
06:41am, Wednesday, 03'rd Jun 2026
Deutsche Bank has kept its sell rating and 11,500p price target on AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), the FTSE 100 pharmaceuticals giant, with the shares at 13,064p. The bank's analyst judged the
AstraZeneca Highlights Sustained Survival Benefit In Advanced Breast Cancer Study
02:26pm, Tuesday, 02'nd Jun 2026
AstraZeneca Plc (NASDAQ:AZN) on Tuesday reported updated Phase 3 SERENA-6 trial results showing that camizestrant combined with a CDK4/6 inhibitor continued to deliver significant progression-free sur
WILMINGTON, Del.--(BUSINESS WIRE)--Further positive results from the Phase III SERENA-6 trial showed AstraZeneca's camizestrant plus a cyclin-dependent kinase (CDK) 4/6 inhibitor – palbociclib, ribo
AstraZeneca PLC (AZN) Stock Down 3.2% but Still Overvalued -- GF Score: 84/100
05:11pm, Monday, 01'st Jun 2026
On June 01, 2026, AstraZeneca PLC (AZN) shares fell 3.2%, closing at $179.71. The stock has seen a 52-week range of $134.90 to $212.71, illustrating a significa
5 Foreign Stocks That Could Beat The S&P 500
02:44pm, Monday, 01'st Jun 2026
James Demmert explains why foreign markets are beating the U.S.—and the five international stocks he thinks can outperform the S&P 500.
AstraZeneca Sees Encouraging Survival Trend In Liver Cancer Trial
01:55pm, Monday, 01'st Jun 2026
AstraZeneca Plc (NASDAQ:AZN) on Monday reported Phase 3 EMERALD-3 trial results showing that its immunotherapy-based STRIDE regimen, when combined with lenvatinib and transarterial chemoembolization (
ASCO 2026: A quiet conference for European pharma, but AstraZeneca and Roche both have work to do
10:02am, Monday, 01'st Jun 2026
This year's American Society of Clinical Oncology (ASCO) conference has been a subdued affair for European pharmaceutical companies, with no major plenary presentations and little data capable of movi
WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from the EMERALD-3 Phase III trial showed AstraZeneca's IMFINZI® (durvalumab) in combination with IMJUDO® (tremelimumab-actl), lenvatinib and tran
BioInvent to Host a KOL Event in Stockholm on June 11, 2026, to Discuss Updated BI-1206 & BI-1808 Data in Hematology
05:20am, Monday, 01'st Jun 2026
LUND, SE / ACCESS Newswire / June 1, 2026 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the discovery of novel immune-modulatory antibodies, today announced that it w
Velan Capital Drops 140,000 Mineralys Therapeutics (MLYS) Shares Worth $4.1 Million
10:19am, Sunday, 31'st May 2026
Mineralys Therapeutics develops novel therapies for resistant hypertension, with its lead candidate advancing through clinical trials.
US bank sees positive risk-reward for AstraZeneca ahead of pivotal heart drug trial
11:33am, Friday, 29'th May 2026
Citi sees the risk-reward balance as favourable for AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) ahead of headline results from a pivotal trial of its heart drug...
